Page 133 - MemoriaER-Eng

www.ciberer.es

Most relevant • García-GiMénez Jl, seco-cerVera M, aGuado c, roMá-Mateo c, dasí F, PrieGo s, MarkoVic
J, knecht e, sanz P, Pallardó FV. Lafora disease fibroblasts exemplify the molecular
scientific
interdependence between thioredoxin 1 and the proteasome in mammalian cells.
articles
Free Radic Biol Med 2013; 2013 Jul 9. [Epub ahead of print].

• P G, t aa, c G, ’i M, P FV, P s, P b, t
aGanoalaMancaastellodschiaallardóetroVicortoiano
l, zatterale a. Bone marrow cell transcripts from Fanconi anaemia patients reveal in
vivo alterations in mitochondrial, redox and DNA repair pathways. Eur J Haematol

2013; 2013 Aug. 91(2):141-51.

• sandoVal J, Peiró-choVa l, Pallardó FV, García-GiMénez Jl. Epigenetic biomarkers in la-
boratory diagnostics: emerging approaches and opportunities. Expert Rev Mol Diagn

2013; 2013 Jun. 13(5):457-71.

• PaGano G, talaManca aa, castello G, d’ischia M, Pallardó FV, PetroVic s, Porto b, tiano l,

zatterale a. From clinical description to in vitro and animal studies, and backwards
to patients: Oxidative stress and mitochondrial dysfunction in Fanconi anaemia. Free
í
Radic Biol Med 2013; 2013 Jan 29. [Epub ahead of print].

• Garca-GiMénez Jl, olaso G, hake s, bönisch c, WiedeMann s, MarkoVic J, dasi F, GiMeno a, é
P-q c, c M, P o, V J, P F. Histone H3 glutathionylation
erezuilisaPdeVilaalaciosinaallardo
in proliferating mammalian cells destabilizes nucleosomal structure. Antioxid Redox
Signal 2013; 2013 Mar 31. [Epub ahead of print].

í
• Saving Live at Birth. Belinda and Bill Gates foundation & USAID and Grand
Highlights
Challenges Canada. Washington, July 2013. Funding of the international project

entitled: “HIST-BIRTH: Innovative and rapid point of-care histone test strips for
é
early diagnosis of sepsis in pregnancy and childbirth”, an international joint project
where the principal investigator is Dr. F. Pallardó. Collaboration between U733/

University of Valencia, the Polytechnic University of Valencia, the International óó

University of Kampala (Uganda) and a private company Bioarray S.L).

• Dr. Jos Luis Garca-Gimnez won the national award for Young Entrepreneurs
INJUVE, given by the Spanish Ministry of Health. The goal of the project awarded

is the constitution of a new R&D company called “Epidisease S.L.”. A Project that é

targets translation of the knowledge in new technologies to innovative analysis in
epigenetics for the improvement of health problems.

• Organization of the course for specialized formation in the Valencian School for

Health Studied (EVES). This training course is addressed to health workers of
í
the Valencian health system. The course (28 hours) entitled: “Rare diseases:
research, clinical care, and social awareness” Code: 31314601a; DOGV: 6944

date: 16.01.2013). Speakers belong to CIBERER, Several National Reference é
centers, CIBERER biobank and Orphanet.

•
Project funding: Study of miRNAs in patients with Friedreich’s Ataxia. Diagnostic 13
and Clinical implications. Strategic Health Action. ISCIIII. PI12/22263. Principal 20
T
Investigator: Federico V. Pallard. Dr. Jos Luis Garca Gimnez has been recognized OR
as “Investigador emergente” by the Research Health Institute INCLIVA . Funding P
RE
of project entitled: “Identification of circulating histones in plasmas from patients L
A
suffering severe sepsis and septic shock”. Funding of the project: “Epigenetic NU
Factors and Adolescent Idiopathic Scoliosis” by The European Society for Spine. N
A
All biological samples of these studies have been stored at the CIBERER-Biobank R /
E
and in the INCLIVA biobank.
ER
B
• Approval of the Master on rare diseases of the University of Valencia-ADEIT. CI
Director Dr. Federico V. Pallard. Code.13721390

133